Daiichi Sankyo Co. (TYO:4568) announced today that it has received FDA approval for AZOR.
AZOR, amlodipine and olmesartan medoxomil, is used in the treatment of hypertension also referred to as high blood pressure. A once daily pill that is a combination of calcium channel blocker and angiotensin receptor blocker.
"AZOR with its established efficacy and favorable side effect profile provides two
complementary mechanisms of action to lower blood pressure. It will give
physicians a new treatment option for patients whose blood pressure remains
too high on currently prescribed medications" stated Michael A. Weber, MD, Professor of Medicine, State University of New York, Downstate College of Medicine.
Hypertension is estimated to affect as many as one in three Americans. It is estimated that 1.6 billion people world wide will have hypertension by the year 2025.
Comment Preview